– USA, TX – Repros Therapeutics Inc. (NASDAQ:RPRX), today announced that it has appointed Mr. Patrick Fourteau to its Board of Directors, where he will serve as Chairman of the Board.

Mr. Fourteau is a seasoned pharmaceutical industry executive having over 35 years of healthcare industry experience, with particular expertise in executing sales strategies for pharmaceutical products, product acquisitions, out-licensing and mergers and acquisitions. He is the President and CEO of New Haven Pharmaceuticals, Inc. He also serves as a member of the board of directors of Insys Therapeutics (INSY).

Mr. Fourteau’s executive roles prior to joining New Haven Pharmaceuticals include President and CEO of Shionogi Pharma, Inc. from 2008 until 2010. Immediately prior, he was President and CEO of Sciele Pharma, the publicly traded specialty pharmaceutical company, during the period when Shionogi acquired Sciele Pharma in 2008 for $1.4 billion. He has held additional executive roles at inVentiv Health, St. Jude Medical Inc. and 19 years as VP of Pharmaceutical Operations for Lilly International.

Mr. Fourteau earned an MBA from Harvard University and both a B.A. and M.A. in mathematics from The University of California, Berkeley.

On accepting the position, Mr. Fourteau stated, “I am delighted to become chairman of Repros during this important period. In Proellex and enclomiphene, the Company has two assets whose potential commercial value must be carefully assessed. I intend to work with the Board in continuing to consider strategies and approaches that will provide Repros the best options to achieve value in the US and other major global markets, thereby enhancing shareholder value.”

Joseph Podolski, President and CEO of Repros commented, “The appointment of Mr. Fourteau as Chairman adds key skills to the Repros Board. We look forward to his input as we continue our efforts to drive shareholder value. I would also like to thank Nola Masterson for her service as Chair over the last several years, and look forward to continuing to work with her as a member of the Board.”

About Repros Therapeutics Inc.

Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.